Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of dapagliflozin in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64